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The expression of functional antibody fragments in Escherichia coli enables a detailed analysis by NMR spectroscopy. This is demonstrated with 
the uniform labeling of an Fv-fragment (25 kDa) comprising the antigen binding site of an anitbody against 2-phenyloxazolone with lSN and W. 
The antigen-complexed Fv-fragment was analysed for a potential assignment by heteronuclear multi-dimensional NMR spectroscopy. For almost 
all backbone amides 15N/‘H crosspeaks and for 80% of them TOCSY crosspeaks were observed. In a 13C-edited-HCCH-2D experiment 17 out 
of 18 threonine spin-systems were identified. Thus detailed assignments are possible, but some amino acid specific labeling in addition to uniform 
labeling will be required for complete assignments of Fv-fragments. 
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1. INTRODUCTION 
High field NMR spectroscopy has now become a 
viable alternative to X-ray crystallography for high- 
resolution structural studies of macromolecules. 
Estimates of the size limit for detailed NMR studies of 
proteins lie between 20 and 30 kDa. In complex 
systems, resonance overlap in homonuclear proton 
spectra can be resolved by the use of heteronuclear ex- 
periments performed with “N- and 13C-enriched 
samples, relying on the greater chemical shift dispersion 
of the heteronucleus [ 11. Concurrently, progress in pro- 
tein engineering has enabled the production of func- 
tional recombinant antibody-subunits in E. coli [2,3] 
and eukaryotic cells [4]. The smallest antibody frag- 
ment which still retains the natural antigen binding site 
is the so-called Fv-fragment. This consists of a pair of 
non-covalently associated heavy and light chain 
variable domains, each of which contains three hyper- 
variable loops forming the antigen binding site. 
Understandably, in none of these cases were more 
detailed assignments attempted. We report here the first 
step of such an attempt with the complete “N- and 13C- 
labeling of a recombinant antibody Fv-fragment 
purified from E. coli cultures. 
2. EXPERIMENTAL 
2. I Protein expre.mion ufld purificulion 
An Fv-fragment has a size of about 25 kDa which 
formally places it within reach of a detailed structural 
analysis in solution by NMR spectroscopy. To date, at- 
tempts in this direction have been restricted to the label- 
ing of specific amino acids in proteolytically obtained 
Fab-fragments ([S] and references therein), a pro- 
teolytically produced Fv-fragment [6] and a recombi- 
nant Fv-fragment expressed in myeloma cells [7] or to 
site-specific identification of amino acid side chains by 
mutagenesis of an Fv-fragment expressed in E. co/i [S]. 
For expression of the Fv-fragment of the anti-2.phenylouarolone 
antibody NQI 1.7.22, a Hindlll/EcoRI-DNA fragment containing 
the light and heavy chain variable regions [8], was cloned into a 
modified verrion of the expression vector pET1 I [9]. The Hin- 
dlll/EcoRI fragment contains ribosome binding sites, the secretory 
leader sequence, of the pectate lyase gene and termination codons for 
the genes of both chains. The pETl1 vector had been modified 
previously (L. Farrell, unpublished) by insertion of an M13-origin 
downstream of the transcription terminator to allow rescue of single 
stranded pla,mid DNA with helper phage. A Hind111 site was in- 
troduced upstream of the Shine-Delgarno sequence in the original 
ptTl1 vector with the mutagenic oligonucleotide 5’.CTA GAA 
ATA AGC TTG TTT AAC-3’ to facilitate the insertion of the Fv- 
fragment expression carsette. 
For expression, the plasmid was transformed into the E. co/i strain 
BI.Zl-DE3 [9]. Isotopically enriched (98%) protein both “N singly 
labeled and 15N/“C doubly labeled FL-fragment - was produced in 
commercial rich medium (CELTONE, Martek Corp., USA), diluted 
3-fold with nitrogen-depleted M9-salts in the presence of 100 mg am- 
picillin per litre. In case of the “N-enriched medium 1% glycerol was 
added as an additional carbon source. 6 ml-cultures, grown at 37°C 
in 20 ml tuber, were induced with 1 mM isopropyl O-D- 
thiogalactopyranoside added together with fresh ampicillin (50 mg/l) 
12-15 hours after inoculation with fresh bacterial colonies. After in- 
cubation at 37°C for a further 24 h, Fv-fragment was purified from 
the culture medium by antigen-affinity chromatography using 
2.phenyloxazolone derivatised EAH-Sepharose [8]. 
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2.2. NMR specfroscopy 
NMR samples were prepared from 8 mg “N- and from 8 mg 
“N/“C-labeled Fv-fragment resulting in a protein concentration of 
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about 0.7 mM. The Fc-fragment/antigen complex \bas dissolved in 5 
mM phosphate, 200 mM NaCI. pH ,,,,,, 6.2 in 8”i1 DzO (“N \amplc) or 
9Y.Yr’n DzO (“N/“C sample). NMK spcctt-a \rere recorded at 313h: on 
a Bruker AhlN-500 \pectrometel usin g a broadband 5 mm probe and 
analyzed bith UXNMR (Bruker) or FELIX (Hare Research) roft- 
\%a,-e. Flomonuclear t\\o-dimcn\ionaI double quantum and T-OCS\i 
spectra were recorded a, dexribed el\e\rhere [Xl. “N/‘H and “C,/‘H 
two-dimensional heteronuclear single quantum coherence (HSQC) 
correlation experiments [IO] were recorded along with “N-filtered- 
TOCSVZD and 3D cuperimentc (recorded lvith an HhlQC-hequcnce 
[l I] after the TOCS\r -spin lock) and a “C~f~ltered~HC’C‘H~2D- 
experiment [12], omitting the indirectly obtained ‘H-dimcnrion and 
carbonyl decoupling. 
3. RESULTS AND DISCUSSION 
The expression of FL/-fragments in a functional, 
secreted form has been demonstrated for various an- 
tibodies [3,4,8,13] using different expression systems. 
Here, for the production of an isotopically enriched Fv- 
fragment in E. co/i, a T7 RNA polymerase expression 
system [9] was used. Expression of the Fv-fragment is 
regulated by a T7 gene 10 promotor. The T7 RNA 
polymerase is provided by the host strain (BL21-DE3) 
on induction. In this system no metabolic repression 
(e.g. addition of glucose) of the polymerase gene prior 
to induction was necessary for optimum yields. Addi- 
tion of a metabolic repressor to prevent leakage rc- 
quired for many expression systems iq not economical 
in the production of labeled protein. Yields here were 
comparable (4-6 mg/l in rich medium) to the previously 
used IacZ-expression system [S], in which 1%~ glucose 
was added for metabolic repression prior to induction. 
In minimal medium yields were generally much lower 
(less than 0.5 m&/I). 
With both the ‘“N- and the “C/‘SN-enriched 
medium, 8 mg functional Fv-fragment were purified 
from 1.5 litres (see Section 2 for details) of commercial 
rich medium derived from algae-culture, enough for 0.7 
mM samples. Although this concentration is extremely 
low for NMR experiments, it is only slightly below the 
maximum of about 1 mM at which the Fv-fragment/an- 
tigen complex starts to aggregate. The solubility of the 
free Fv-fragment is even lower than 1 mM. Other FL:- 
fragments are similarly or even less soluble (unpublish- 
ed). For the NMR experiments the Fv-fragment was 
complexed with a 4-fold excess of the ligand 
4-glycyl-2-phenyl-oxazolone [S]. 
In Fig. 1 the spectrum from an “N/‘H-correlated 
HSQC experiment recorded with the 15N singly labeled 
Fv-fragment/phenyloxazolone complex is shown. 245 
possible peptide backbone “N/‘H crosspeaks are 
reasonably well resolved. The Fv-fragment has 229 non- 
proline residues, 8 asparagines and 14 glutamines, thus 
almost all backbone amides are observed in the simple 
“N/‘H-correlation experiment. In “N-edited-2D and 
3D-TOCSY experiments (isotropic mixing time = 26 
ms (2D) or 22 ms (3D), not shown) crosspeaks were 











Fiy. I. Spectrum ft-om a “Y ‘H-HSQC‘C‘\~CI imcnt tecot-detl \\ith 0.7 
m\I “N-labeled I.\-fragmcn~ complexed wilh 2.8 m%l li~and in Y2°b 
fl>O S”0 D20. 
some n-protons are very close to the Hz0 signal (see 
Fig. 2a) and may have been saturated in our 15N-edited 
TOCSY experiments in Hz0 by employing water sup- 
pression. 
Fig. 2a originates from a ‘“Ci’H-correlated HSQC- 
experiment recorded n,ith the “N/‘3C-labeled sample in 
DzO. The problem of overlap in the (u-carbon region 
sho\vn here is very obvious. However, assignments are 
not impossible, as 17 out of 18 threonine side chains 
were identified using a 2D-HCCH experiment (Fig. 2~) 
in combination with homonuclear double quantum (not 
shown) and TOCSY-spectra (Fig. 2b) recorded with the 
unlabeled F\-fragment. The general overlap in the (Y 
region made it impossible to distinguish many threoninc 
from alanine spin systems in the homonuclear ex- 
periments. In the HCCH experiment the difference in 
the “C chemical shift of alanine-oc-carbons (- 50 ppm) 
and threoninc-o-carbons ( - 20 ppm), \t hose attached 
protons lie in the same chemical shift range, enabled 
assignment. Also ‘H-chemical shift degeneracies of dif- 
ferent threonincs (e.g. Thr-12 and Thr-13 in Fig. 2a) 
were resolved in the “C-dimension. 
However, low sensitivity due to fast relaxation of the 
Fv-fragment (T, = 1.1 s) \vill make assignment of many 
spin systems very difficult or impossible, \chen no help 
like the strong -r//3 crosspeak in case of the threonines 
is available. Therefore amino acid specific labeling is 
likely to be necessary for sequence specific assignments 
even when triple resonance experiments (HCACO, 
HNCA, HNCO, [l]) for the assignment of the pcptide 
backbone are used. 
Based on these results we can now formulate a 
strategy for the assignment of antibody Fc-fragments. 
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Fig. 2. Sections from, (a) a ‘-‘C/‘H-HSQC-2D and (c) a HCCH-2D experiment recorded with 0.7 mM “C/“N-labeled F\-fragment complexed 
\\ith 2.8 mM ligand in D20. and (b) a ‘H-TOCSY-ZIJ ekpcriment recorded lvith 1 mM unlabeled Fv-fragment complexed with 4 mM ligand. The 
threonine spin system\ are emphasized by numberins. 
Most of the protons of the Fv-fragment are observed 
and may in principle be identified through sufficient ef- 
fort in, for example, amino acid-type-specific isotopic 
labeling. This is certainly a good investment in the case 
of a ‘prototype’ Fv-fragment if its P-sheet frameworks 
(comprising more than 80% of an Fv-fragment) are 
later used in combination with ‘binding-site loops’ from 
other antibodies, as in the case of reshaped human an- 
tibodies, when murine binding sites were grafted on to 
a human P-sheet framework 1141. In this situation, 
subsequent assignments may be based largely upon the 
signals of the prototype Fv-fragment. 
However, complete assignments may not be 
necessary in each case, given the number of antibody 
structures available from crystallographic studies [IS]. 
A more economical approach will often be the use of 
the heteronuclear NMR experiments for assignments in 
specific regions such as the antigen binding site. Iden- 
tification of NMR-signals from key residues can be in- 
itiated by site-directed mutagenesis [8]. When 
assignments are then extended to the backbone, model- 
ing of the binding site in combination with an assumed 
framework structure seems a much more feasible task 
than analysis of the whole Fv-fragment. 
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